TD Private Client Wealth LLC Cuts Position in DaVita Inc. $DVA

Key Points

• TD Private Client Wealth LLC significantly reduced its position in DaVita Inc. by 92.4%, selling 5,272 shares, and now holds only 431 shares valued at $61,000.
• Other institutional investors have increased their stakes in DaVita, with notable increases from Invesco Ltd. (3.4% increase) and Northern Trust Corp (20.2% increase).
• DaVita's latest earnings report showed a quarterly EPS of $2.95, exceeding estimates and representing a year-over-year revenue growth of 6.1%.

TD Private Client Wealth LLC trimmed its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 92.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 431 shares of the company's stock after selling 5,272 shares during the quarter. TD Private Client Wealth LLC's holdings in DaVita were worth $61,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DVA. Invesco Ltd. lifted its holdings in shares of DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company's stock valued at $251,322,000 after buying an additional 53,402 shares during the period. Northern Trust Corp lifted its holdings in shares of DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company's stock valued at $136,240,000 after buying an additional 149,858 shares during the period. Gates Capital Management Inc. lifted its holdings in shares of DaVita by 0.7% in the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company's stock valued at $110,476,000 after buying an additional 4,698 shares during the period. Amundi lifted its holdings in shares of DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company's stock valued at $79,584,000 after buying an additional 71,304 shares during the period. Finally, Epoch Investment Partners Inc. lifted its holdings in shares of DaVita by 10.7% in the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company's stock valued at $62,400,000 after buying an additional 39,485 shares during the period. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Price Performance

NYSE:DVA opened at $130.66 on Tuesday. DaVita Inc. has a 12 month low of $126.07 and a 12 month high of $179.60. The stock has a 50 day moving average of $135.98 and a two-hundred day moving average of $140.44. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The firm has a market cap of $9.34 billion, a P/E ratio of 12.85, a price-to-earnings-growth ratio of 0.94 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%.The company had revenue of $3.38 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same period in the previous year, the business earned $2.00 EPS. DaVita's quarterly revenue was up 6.1% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on DVA. Truist Financial set a $148.00 price objective on DaVita in a report on Friday, August 8th. Barclays decreased their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. Bank of America reduced their price target on DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a report on Wednesday, September 10th. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a report on Saturday, September 13th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus target price of $158.00.

Insider Buying and Selling

In other news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total value of $352,650.00. Following the completion of the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.50% of the company's stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.